‘IMMUNE Pharmaceuticals’ Partners With Weizmann Institute

IMMUNE Pharmaceuticals, a developer of monoclonal antibodies, and Yeda, the technology transfer company of the Weizmann Institute of Science, announced a broad collaboration to develop antibody therapeutics focusing on the development of new cancer treatments. IMMUNE Pharmaceuticals, an Israel and US based biopharmaceutical company, focuses on the development of next generation monoclonal antibodies addressing the treatment of cancer and inflammatory diseases.